J Korean Med Sci.  2003 Apr;18(2):218-224. 10.3346/jkms.2003.18.2.218.

Expression of Cyclooxygenase-2 and Its Correlation with Clinicopathologic Factors of Ampulla of Vater Cancer

• Kim HJ
• Sohn TS
• Lee KT
• Lee JK
• Paik SW
• Rhee JC

• KMID: 2157625
• DOI: http://doi.org/10.3346/jkms.2003.18.2.218

Abstract

There has been no report for the expression of cyclooxygenase-2 (COX-2) and its clinicopathologic and biologic significance in ampulla of Vater cancer. This study was aimed for the clarification of COX-2 expression and its biologic roles in ampulla of Vater cancer. Fourty-six patients with ampulla of Vater cancer were enrolled and their COX-2 expression and clinicopathologic features were analyzed. The median age of patients was 60 yr and the mean duration of follow-up was 35 months (range: 14-82 months). Immunohistochemical stainings for COX-2, Ki-67, CD34 and TUNEL staining were performed. The immunoreactive COX-2 expression was present in 24 (52.2%) patients of ampulla of Vater cancer and mainly localized in cytosolic and perinuclear region. There was no significant difference in the length of survival between COX-2 postive and negative group (p=0.9420 by Log Rank test). Also, there were no significant differences of proliferation index (p=0.326), apoptotic index (p=0.764) and microvessel density (p=0.135) between COX-2 positive and negative group. Initial pTNM stage (p=0.0028 by Log Rank test) and blood transfusion over 4 pints during operation (p=0.0254 by Log Rank test) were independent prognostic factor in patients with ampulla of Vater cancer. It is suggested that immunoreactivity of COX-2 is not correlated with clinicopathologic and biologic features of ampulla of Vater cancer.

Keyword

Vater's Ampulla; Duodenal Neoplasms; Prostaglandin-Endoperoxide Synthase; Ki-67 antigen; Apoptosis; Antigen CD34

MeSH Terms

Adult
Aged
Ampulla of Vater*/enzymology
Ampulla of Vater*/pathology
Common Bile Duct Neoplasms/enzymology*
Common Bile Duct Neoplasms/pathology*
Female
Human
Immunoenzyme Techniques
Isoenzymes/metabolism*
Male
Middle Aged
Prostaglandin-Endoperoxide Synthase/metabolism*
Statistics
Survival Rate